Cart
sales@molnova.com
Insulin degludec
CAS No. 844439-96-9
Insulin degludec ( —— )
Catalog No. M25046 CAS No. 844439-96-9
Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by type 1 and type 2 dabetes. Insulin degludec shows binding efficiency with an IC50 value of 19.59 nM/L for insulin receptor. Insulin degludec can be used for the research of type 1 and type 2 diabetes.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 298 | In Stock |
|
| 10MG | 496 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameInsulin degludec
-
NoteResearch use only, not for human use.
-
Brief DescriptionInsulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by type 1 and type 2 dabetes. Insulin degludec shows binding efficiency with an IC50 value of 19.59 nM/L for insulin receptor. Insulin degludec can be used for the research of type 1 and type 2 diabetes.
-
DescriptionInsulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by type 1 and type 2 dabetes. Insulin degludec shows binding efficiency with an IC50 value of 19.59 nM/L for insulin receptor. Insulin degludec can be used for the research of type 1 and type 2 diabetes.Insulin degludec (0.001-1000 nM; 12 h) binds with insulin receptor with an IC50 value of 19.59 nM/L.Insulin degludec (200 nM; 10 min) increases glucose uptake in HL-1 cells.
-
In VitroInsulin degludec (0.001-1000 nM; 12 h) binds with insulin receptor with an IC50 value of 19.59 nM.Insulin degludec (200 nM; 10 min) increases glucose uptake in HL-1 cells. Western Blot Analysis Cell Line:HL-1 cardiomyocytes Concentration:200 nM Incubation Time:0-60 min Result:Decreased the level of Akt phosphorylation after 5 and 10min treatment.
-
In VivoInsulin degludec (5 U/kg; s.c. once daily for 30 days) affects glucose homeostasis and liver metabolism in diabetic mice undergoing insulin-induced hypoglycemia. Animal Model:Male Swiss mice with diabetes Dosage:5 U/kg Administration:Subcutaneous injection; 5 U/kg once daily for 30 days Result:Showed a fast response to insulin-induced hypoglycemia with a glycemic level at or slightly under 100 mg/dl after 60 min and this response effect can be abolished by cortisol. Diminished rates of glucose production and showed a low lactate production in livers. Increased the number of hepatocytes.
-
Synonyms——
-
PathwayTyrosine Kinase
-
TargetInsulin Receptor
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number844439-96-9
-
Formula Weight——
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility0.1 M HCL : 50 mg/mL (ultrasonic and adjust pH to 2 with 0.1 M HCL)
-
SMILESN/A
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Bataglini C, et al. Insulin degludec and glutamine dipeptide modify glucose homeostasis and liver metabolism in diabetic mice undergoing insulin-induced hypoglycemia. J Appl Biomed. 2021 Dec;19(4):210-219.
2. Hartmann T, et al. Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function. Cardiovasc Diabetol. 2016 Jul
molnova catalog
related products
-
Insulin Receptor 114...
[pTyr1146][pTyr1150][pTyr1151]Insulin Receptor (1142-1153) binds to insulin and can be used as insulin receptor tyrosine kinase substrates.
-
MSDC-0160
A new generation insulin sensitizer and mitochondrial target of thiazolidinediones (mTOT) modulator that has low affinity for binding and activation of PPARγ (EC50=23.7 uM).
-
[D-Ala2]-GIP (human)
Highly potent GIP receptor agonist (EC50 = 630 ± 119 pM). Displays equivalent cAMP stimulating properties and improved resistance to enzymatic degradation compared to native GIP in cells expressing wild type GIP receptor. Improves glucose tolerance, insulin release and cognitive function in various animal models of obesity and diabetes. Displays neuroprotective effects in an MPTP model of PD.
